Skip to main content

Supreme Court Refuses To Hear Opioid Overdose Death Lawsuit

Supreme Court Refuses To Hear Opioid Overdose Death Lawsuit

Supreme Court Refuses To Hear Opioid Overdose Death Lawsuit

Introduction

On December 3, 2018, the U.S. Supreme Court refused to hear a petition filed by the parents of a National Hockey League player. The petition stated that the player lost his life due to an overdose of opioids prescribed by the team doctors. The ruling ended the five-year-old litigation in which the player's parents blamed NHL for his recurring concussions during his career.

The player, who died at the age of 28 in 2011, played for the Minnesota Wild and the New York Rangers; an autopsy revealed he suffered from chronic traumatic encephalopathy, or CTE, a devastating brain condition common among ice-hockey players. His parents filed a wrongful death lawsuit in 2013 against NHL and argued that a trial judge improperly tossed the suit under a Minnesota procedural rule, which requires wrongful death and other survival actions to be presented by a court-appointed trustee. The U.S. Court of Appeals for the Seventh Circuit found that the family fortified their claims by failing to respond to the NHL's argument that the complaint filed against the league was unjust. The U.S. District Court for the Northern District of Illinois dismissed the case in 2017 and warned that the ruling, “should not be read to commend how the NHL handled the victim's particular circumstances or the circumstances of other NHL players who over the years have suffered injuries from the on-ice play.''

Opioid overdose death lawsuits are consolidated as a part of multidistrict litigation, MDL No. 2804 (In Re: National Prescription Opiate Litigation) in the Northern District of Ohio before U.S. District Judge Dan A. Polster. The first bellwether trial in the litigation has been scheduled for September 3, 2019.

Allegations are made against opioid manufacturers that they violated the rules by not informing the Federal authorities about the unusual size, suspicious purchases, or the frequency of bulk purchases. There is an allegation that huge benefits were reaped by manufacturers, and they intentionally failed to inform the medical providers about the addictive nature and consequences of opioids.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.